Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
BOTJ$24.14+0.46(+1.96%)Bank of the James Financial Group Announces Third Quarter of 2026 and First Nine Months of 2026 Financial Results and Declaration of Cash Dividend; Increases Quarterly Cash Dividend by 50%[12:00:00 PM ET]VST$137.10-3.85(-2.74%)Vistra Completes Acquisition of Cogentrix Energy, Expanding Diverse Generation Fleet Vistra Corp. (NYSE: VST) today announced it has completed the acquisition of Cogentrix Energy, consisting of 10 modern natural gas generation...[12:00:00 PM ET]PCG$13.12-0.11(-0.83%)PG&E Makes History as First Energy Utility to Earn International Emergency Management Accreditation Pacific Gas and Electric Company (PG&E) has become the first energy utility in the world to earn accreditation from the Emergency Management...[12:00:00 PM ET]MDLZ$64.80+2.27(+3.62%)UNDERCOVER SNACKS ANNOUNCES MAJORITY INVESTMENT BY MONDELĒZ INTERNATIONAL Undercover Snacks, the innovative better-for-you snack company known for its delicious chocolate-covered and frosted quinoa crisps, today announced a ...[11:53:00 AM ET]TOL$144.74+0.47(+0.32%)Toll Brothers Announces New Luxury Home Collection Coming Soon to Toll Brothers at Mapleton near Provo, Utah[11:46:22 AM ET]GBHL$0.000.00(0.00%)Global Entertainment Holdings Closes Stock Purchase Agreement with PYX Wallets and Changes Name to PyX Wallets Inc.[11:45:00 AM ET]AIBT$0.00-0.00(-6.98%)AIBotics Clarifies Recent Increase in Shares Outstanding Following Insider Debt-to-Equity Conversions[11:30:49 AM ET]PESI$12.72-0.60(-4.50%)Perma-Fix Schedules Third Quarter 2026 Business Update Conference Call[11:30:00 AM ET]OMC$80.70-0.28(-0.34%)Adform's MCP Server Transforms Workflows for Omnicom Media and Publicis[11:30:00 AM ET]

PCVX · NASDAQ

Vaxcyte, Inc.

$61.51 -1.08 (-1.72%)

Company overview

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine currently in Phase 1/2 clinical trials for the treatment of invasive pneumococcal disease and pneumonia. The company is also developing VAX-XP to protect against emerging strains and address antibiotic resistance, VAX-A1, a conjugate vaccine candidate designed to treat Group A Streptococcus, and VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$9.7B
Employees
414
Headquarters
San Carlos, CA
Website
vaxcyte.com
CEO
Grant E. Pickering
Listed
June 12, 2020
P/E
-8.89
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
-$5.9M
Operating income
-$1.1B
EBITDA
-$946M
Net income
-$947M
EPS
-$6.89
Total assets
$3.3B
Total debt
$116M
Earnings yield
-11.25%

Revenue segmentation

By product (FY 2021)
By region (FY 2021)

No geographic segmentation.

Showing FY 2021

Price chart

43.4855.7568.0380.3092.57
PCVX 1D NASDAQ O62.36H63.14L61.93C62.59+1.13 (+1.83%)Vol626.13K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
PCVXVaxcyte, Inc. Stock news Wall Street Analysts See an 87.35% Upside in Vaxcyte (PCVX): Can the Stock Really Move This High? Zacks Investment Research
PCVXVaxcyte, Inc. Stock news Vaxcyte, Inc. (NASDAQ:PCVX) Stock Rated “Moderate Buy” by Sell-Side Brokerages Defense World
PCVXVaxcyte, Inc. Stock news Wall Street Analysts Think Vaxcyte (PCVX) Could Surge 75.6%: Read This Before Placing a Bet Zacks Investment Research
PCVXVaxcyte, Inc. Stock news Vaxcyte (NASDAQ: PCVX) raises $575 million with notes and stock sale Defense World
PCVXVaxcyte, Inc. Press release Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Convertible Senior Notes GlobeNewswire
PCVXVaxcyte, Inc. Press release Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes GlobeNewsWire
PCVXVaxcyte, Inc. Stock news Vaxcyte: 'Strong Buy' On VAX-31 Trial Win IPD VAX-31 And Additional Readouts 1st Half 2027 Seeking Alpha
PCVXVaxcyte, Inc. Stock news Crude Oil Edges Lower; Lamb Weston Shares Surge Following Upbeat Q1 Earnings Benzinga
PCVXVaxcyte, Inc. Stock news Vaxcyte (NASDAQ:PCVX) Sees Large Volume Increase Following Analyst Upgrade Defense World
PCVXVaxcyte, Inc. Stock news Vaxcyte’s VAX-31 Meets All Primary Endpoints in Pivotal Phase III OPUS-1 Trial Defense World
GSHD Stock news Goosehead Insurance, Decent Holding And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session Benzinga
PCVXVaxcyte, Inc. Stock news Vaxcyte's VAX-31 Meets All Primary Endpoints in Pivotal Phase III OPUS-1 Trial MarketBeat
PCVXVaxcyte, Inc. Press release Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes GlobeNewsWire
PCVXVaxcyte, Inc. Stock news Vaxcyte, Inc. (PCVX) Discusses Top Line Results From OPUS-1 Phase 3 Trial of VAX-31 Pneumococcal Vaccine Candidate Transcript Seeking Alpha
PCVXVaxcyte, Inc. Stock news Vaxcyte shares surge on late-stage vaccine trial success Proactive Investors
PCVXVaxcyte, Inc. Stock news Vaxcyte Stock Spikes 57% as Lead Vaccine Candidate Takes Aim at Pfizer and Merck Barrons
PCVXVaxcyte, Inc. Stock news RXO, Vaxcyte, PTC And Other Big Stocks Moving Higher On Monday Benzinga
PCVXVaxcyte, Inc. Stock news Vaxcyte Stock Hits New 52-Week High - Here's Why Benzinga
PCVXVaxcyte, Inc. Press release Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company's 31-Valent Pneumococcal Conjugate Vaccine Candidate GlobeNewsWire
PCVXVaxcyte, Inc. Press release Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company's 31-Valent Pneumococcal Conjugate Vaccine Candidate GlobeNewsWire
See more
FAQ

Questions about Vaxcyte, Inc.

What does Vaxcyte, Inc. do?
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine currently in Phase 1/2 clinical trials for the treatment of invasive pneumococcal disease and pneumonia. The company is also developing VAX-XP to protect against emerging strains and address antibiotic resistance, VAX-A1, a conjugate vaccine candidate designed to treat Group A Streptococcus, and VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
What is PCVX's market cap?
Vaxcyte, Inc. (PCVX) is a listed stock with a live quote. The latest market cap on this page is $9.7B.
Where is Vaxcyte, Inc. headquartered?
Vaxcyte, Inc. is headquartered in San Carlos, CA.
How do I get PCVX news from the API?
Call GET /v1/news?tickers=PCVX. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does PCVX news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for PCVX, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the PCVX price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs